Abstracts

768 – High Mortality From TB–Histoplasmosis Coinfection in HIV in Latin America and the Caribbean

Background Tuberculosis (TB) and histoplasmosis are leading opportunistic infections (OIs) among people with advanced HIV disease (AHD) in Latin America and the Caribbean (LAC). Concomitant histoplasmosis, present in 15-40% of TB cases, poses a major therapeutic challenge due to drug–drug interactions and overlapping toxicities. Data on the prevalence, outcomes, and optimal treatment regimens remain limited.…

769 – Single-Dose Liposomal Amphotericin B for Cryptococcal Meningitis in Low-Resource Settings

Background In 2022, the World Health Organization recommended a single high-dose liposomal amphotericin B (L-AmB) regimen with fluconazole and flucytosine as induction therapy for cryptococcal meningitis. This was based on the AMBITION trial which showed 2-week and 10-week mortality of 13% and 24% with reduced toxicity in comparison to 7-days of conventional amphotericin B. Data…

542 – Ibalizumab Demonstrates Real-World Durability in People Living With Multidrug Resistant HIV

Background There are ~1.2 million people with HIV (PWH) in the United States. Among them, ~1% are heavily treatment-experienced (HTE) and harbor multidrug-resistant (MDR) HIV-1. MDR HIV-1 is most observed in individuals with extensive prior exposure to antiretroviral therapies (ARVs). For this underrepresented and clinically complex population, achieving and sustaining virologic suppression remains a significant…

552 – Next-Generation Sequencing of HIV Resistance in Dolutegravir Failure Under Variable Drug Pressure

Background In South Africa (SA), virological failure on dolutegravir (DTG)-based regimens is often driven by suboptimal adherence. Next-generation sequencing (NGS) may detect resistance mutations more sensitively than conventional Sanger sequencing. We investigated the added value of NGS in samples with and without detectable DTG drug pressure. Methods  We established an IonTorrent AmpliSeq HIVDR NGS workflow…

840 – Neutralizing Antibody, VRC01, PK & Safety Among Infants Initiating Very Early ART in IMPAACT P1115 

Background Very early antiretroviral treatment (ART) with effective viral suppression can enable ART-free remission in infants with in utero HIV. However, many infants do not achieve sustained viral suppression. Anti-HIV broadly neutralizing antibodies (bNAbs), such as VRC01, added to ART may enhance viral suppression but infant PK and safety data for bNAbs are limited. Methods Infants…

590 – DDR Spain Study: Nationwide Reflex Testing and Characterization of Hepatitis Delta Virus Infection

Background Hepatitis delta virus (HDV) infection in people with hepatitis B virus (HBV) accelerates the progression of liver disease and is associated with a higher risk of cirrhosis and hepatocellular carcinoma. The DDR Spain initiative was designed to harmonize HDV diagnosis across the country through reflex anti-HDV and HDV-RNA testing, while providing a comprehensive description…

349 – IL-10 and IFN Signaling Define Epigenetic States Linked to HIV Persistence in Memory CD4+ T Cells

Background HIV persistence during antiretroviral therapy (ART) is sustained by immunoregulatory pathways that suppress antiviral responses. IL-10 has been linked to reservoir size and shown to inhibit interferon stimulated genes (ISG). In SIV-infected rhesus macaques (RMs), anti-IL-10 alone (aIL10) led to partial control of viremia after treatment interruption, highlighting IL-10 as a regulator of reservoir…

1097 – Lost Patients and Missed Cases: Failures of Point-of-Care Diagnostics in Advanced HIV Care

Background Point-of-care (POC) diagnostics are central to the World Health Organisation (WHO) advanced HIV disease (AHD) care package, but their effectiveness in real-world programs is limited by implementation gaps that reduce test performance. We evaluated challenges in POC cryptococcal antigen (CrAg) and CD4 testing across three Médecins Sans Frontières (MSF) supported programs. Methods Evaluations were…